Gilead Sciences scores big wins on multiple fronts: positive Remdesivir trial results, soaring profits from HIV and cancer drugs, and a blockbuster Immunomedics acquisition. CEO predicts robust drug pipeline, expecting results from dozens of clinical trials in 2024. Investors take note, Gilead is on the rise!